Special Issue "Feature Papers"

Quicklinks

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 December 2012)

Special Issue Editor

Guest Editor
Prof. Dr. Diane M. Harper

Professor of Family and Geriatric Medicine, Obstetrics and Gynecology, Bioengineering, Epidemiology and Population Health, Health Promotions and Behavioral Sciences, University of Louisville School of Medicine, 501 East Broadway, Louisville, KY 40202, USA
E-Mail
Interests: cervical cancer prevention; HPV vaccine, HPV prevention; HPV cure; CIN detection; CIN cure; quality of life; shared decision making; communications

Published Papers (3 papers)

View options order results:
result details:
Displaying articles 1-3
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle The Potential Impact of Preventive HIV Vaccines in China: Results and Benefits of a Multi-Province Modeling Collaboration
Vaccines 2015, 3(1), 1-19; doi:10.3390/vaccines3010001
Received: 15 October 2014 / Accepted: 19 November 2014 / Published: 5 January 2015
PDF Full-text (604 KB) | HTML Full-text | XML Full-text
Abstract
China’s commitment to implementing established and emerging HIV/AIDS prevention and control strategies has led to substantial gains in terms of access to antiretroviral treatment and prevention services, but the evolving and multifaceted HIV/AIDS epidemic in China highlights the challenges of maintaining that response.
[...] Read more.
China’s commitment to implementing established and emerging HIV/AIDS prevention and control strategies has led to substantial gains in terms of access to antiretroviral treatment and prevention services, but the evolving and multifaceted HIV/AIDS epidemic in China highlights the challenges of maintaining that response. This study presents modeling results exploring the potential impact of HIV vaccines in the Chinese context at varying efficacy and coverage rates, while further exploring the potential implications of vaccination programs aimed at reaching populations at highest risk of HIV infection. A preventive HIV vaccine would add a powerful tool to China’s response, even if not 100% efficacious or available to the full population. Full article
(This article belongs to the Special Issue Feature Papers)
Open AccessArticle Factors Affecting the Acceptance of Pandemic Influenza A H1N1 Vaccine amongst Essential Service Providers: A Cross Sectional Study
Vaccines 2013, 1(1), 17-33; doi:10.3390/vaccines1010017
Received: 17 October 2012 / Revised: 3 December 2012 / Accepted: 13 December 2012 / Published: 20 December 2012
PDF Full-text (763 KB) | HTML Full-text | XML Full-text
Abstract
Although mentioned in the UK pandemic plan, essential service providers were not among the priority groups. They may be important targets of future influenza pandemic vaccination campaigns. Therefore, we conducted a cross-sectional survey among 380 employees from West Midlands police headquarters and 15
[...] Read more.
Although mentioned in the UK pandemic plan, essential service providers were not among the priority groups. They may be important targets of future influenza pandemic vaccination campaigns. Therefore, we conducted a cross-sectional survey among 380 employees from West Midlands police headquarters and 15 operational command units in the West Midlands Area during December 2009–February 2010 to identify factors affecting intention to accept the pandemic influenza A (H1N1) vaccine. One hundred and ninety nine (52.4%) employees completed the questionnaire. 39.7% were willing to accept the vaccine. The most common reasons for intention to accept were worry about catching Swine Flu (n = 42, 53.2%) and about infecting others (n = 40, 50.6%). The most common reason for declination was worry about side effects (n = 45, 57.0%). The most important factor predicting vaccine uptake was previous receipt of seasonal vaccine (OR 7.9 (95% CI 3.4, 18.5)). Employees aged <40 years, males, current smokers, and those who perceived a greater threat and severity of swine flu were also more likely to agree to the vaccine. The findings of this study could be used to improve future pandemic immunization strategies. Targeted education programs should be used to address misconceptions; the single most important factor which might lead to a large improvement in uptake is to allay concern about side effects. Full article
(This article belongs to the Special Issue Feature Papers)

Review

Jump to: Research

Open AccessReview Tumor-Associated Glycans and Immune Surveillance
Vaccines 2013, 1(2), 174-203; doi:10.3390/vaccines1020174
Received: 18 April 2013 / Revised: 18 April 2013 / Accepted: 6 June 2013 / Published: 17 June 2013
Cited by 6 | PDF Full-text (680 KB) | HTML Full-text | XML Full-text
Abstract
Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in
[...] Read more.
Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in clinical applications. T-cells, being a part of the adaptive immune response, are the most popular component of the immune system considered for targeting tumor cells. However, for TACAs, T-cells take a back seat to antibodies and natural killer cells as first-line innate defense mechanisms. Here, we briefly highlight the rationale associated with the relative importance of the immune surveillance machinery that might be applicable for developing therapeutics. Full article
(This article belongs to the Special Issue Feature Papers)

Journal Contact

MDPI AG
Vaccines Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
vaccines@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Vaccines
Back to Top